340 related articles for article (PubMed ID: 28131805)
1. Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures.
Stray KM; Park Y; Babusis D; Callebaut C; Cihlar T; Ray AS; Perron M
Antiviral Res; 2017 Apr; 140():116-120. PubMed ID: 28131805
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.
Callebaut C; Stepan G; Tian Y; Miller MD
Antimicrob Agents Chemother; 2015 Oct; 59(10):5909-16. PubMed ID: 26149992
[TBL] [Abstract][Full Text] [Related]
3. Tenofovir alafenamide does not inhibit mitochondrial function and cholesterol biosynthesis in human T lymphoblastoid cell line.
Li M; Zhou L; Dorsey HG; Musoff C; Jnr DA; Schoen N; Djan K; Paintsil E
Antiviral Res; 2020 Nov; 183():104948. PubMed ID: 32980447
[TBL] [Abstract][Full Text] [Related]
4. Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog-Associated Mutations and M184V.
Margot N; Ram R; Abram M; Haubrich R; Callebaut C
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988104
[TBL] [Abstract][Full Text] [Related]
5. High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate.
Margot NA; Liu Y; Miller MD; Callebaut C
Antiviral Res; 2016 Aug; 132():50-8. PubMed ID: 27208653
[TBL] [Abstract][Full Text] [Related]
6. Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro.
Margot NA; Johnson A; Miller MD; Callebaut C
Antimicrob Agents Chemother; 2015 Oct; 59(10):5917-24. PubMed ID: 26149983
[TBL] [Abstract][Full Text] [Related]
7. Antiviral activity of tenofovir alafenamide (TAF) against HIV-1 clinical isolates harboring K65R.
Cox S; Margot N; Callebaut C
J Med Virol; 2023 Apr; 95(4):e28723. PubMed ID: 37185867
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate.
Yager JL; Brooks KM; Castillo-Mancilla JR; Nemkov C; Morrow M; Peterson S; Ibrahim M; Bushman L; Kiser JJ; MaWhinney S; Anderson PL
AIDS; 2021 Dec; 35(15):2481-2487. PubMed ID: 34482350
[TBL] [Abstract][Full Text] [Related]
9. Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).
Imaz A; Niubó J; Cottrell ML; Perez E; Kashuba ADM; Tiraboschi JM; Morenilla S; Garcia B; Podzamczer D
Clin Infect Dis; 2019 Sep; 69(8):1403-1409. PubMed ID: 30561517
[TBL] [Abstract][Full Text] [Related]
10. Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART.
Okochi H; Louie A; Phung N; Zhang K; Tallerico RM; Kuncze K; Spinelli MA; Koss CA; Benet LZ; Gandhi M
Drug Test Anal; 2021 Jul; 13(7):1354-1370. PubMed ID: 33742745
[TBL] [Abstract][Full Text] [Related]
11. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Podany AT; Bares SH; Havens J; Dyavar SR; O'Neill J; Lee S; Fletcher CV; Swindells S; Scarsi KK
AIDS; 2018 Mar; 32(6):761-765. PubMed ID: 29334548
[TBL] [Abstract][Full Text] [Related]
12. The Lymphoid Tissue Pharmacokinetics of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in HIV-Infected Persons.
Fletcher CV; Podany AT; Thorkelson A; Winchester LC; Mykris T; Anderson J; Jorstad S; Baker JV; Schacker TW
Clin Pharmacol Ther; 2020 Nov; 108(5):971-975. PubMed ID: 32385902
[TBL] [Abstract][Full Text] [Related]
13. Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus.
Ray AS; Fordyce MW; Hitchcock MJ
Antiviral Res; 2016 Jan; 125():63-70. PubMed ID: 26640223
[TBL] [Abstract][Full Text] [Related]
14. Establishment of intracellular tenofovir-diphosphate as the key determinant for in vitro-in vivo translation of antiviral efficacy.
Ma B; Barth A; McHale CM; Lai MT
Antiviral Res; 2018 Mar; 151():1-3. PubMed ID: 29337165
[TBL] [Abstract][Full Text] [Related]
15. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.
Ruane PJ; DeJesus E; Berger D; Markowitz M; Bredeek UF; Callebaut C; Zhong L; Ramanathan S; Rhee MS; Fordyce MW; Yale K
J Acquir Immune Defic Syndr; 2013 Aug; 63(4):449-55. PubMed ID: 23807155
[TBL] [Abstract][Full Text] [Related]
16. Blood immune cells from people with HIV on antiviral regimens that contain tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) have differential metabolic signatures.
Ritou E; Satta S; Petcherski A; Daskou M; Sharma M; Vasilopoulos H; Murakami E; Shirihai OS; Kelesidis T
Metabolism; 2023 Apr; 141():155395. PubMed ID: 36842771
[TBL] [Abstract][Full Text] [Related]
17. Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis.
Taneva E; Crooker K; Park SH; Su JT; Ott A; Cheshenko N; Szleifer I; Kiser PF; Frank B; Mesquita PM; Herold BC
Antimicrob Agents Chemother; 2015 Dec; 60(3):1667-75. PubMed ID: 26711762
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.
Markowitz M; Zolopa A; Squires K; Ruane P; Coakley D; Kearney B; Zhong L; Wulfsohn M; Miller MD; Lee WA
J Antimicrob Chemother; 2014 May; 69(5):1362-9. PubMed ID: 24508897
[TBL] [Abstract][Full Text] [Related]
19. Effect of P-glycoprotein and Cotreatment with Sofosbuvir on the Intestinal Permeation of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Fumarate.
Huliciak M; Lhotska I; Kocova-Vlckova H; Halodova V; Dusek T; Cecka F; Staud F; Vokral I; Cerveny L
Pharm Res; 2023 Sep; 40(9):2109-2120. PubMed ID: 37594591
[TBL] [Abstract][Full Text] [Related]
20. Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations.
Callebaut C; Liu Y; Babusis D; Ray A; Miller M; Kitrinos K
PLoS One; 2017; 12(2):e0169948. PubMed ID: 28182625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
